Mahamaya Lifesciences
November 11, 2025 – November 13, 2025
| Price | ₹108 - ₹114 |
| GMP Rumors * | ₹0 |
|---|---|
| Lot size | 1200 |
| Issue size | ₹70.44 cr |
| Allotment | Nov 14, 2025 |
| Listing | Nov 18, 2025 |
Mahamaya Lifesciences Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| INDIVIDUAL | 2 | 2400 | 273600 | 858 |
| sHNI | 3 | 3600 | 410400 | 82 |
| bHNI | 8 | 9600 | 1094400 | 163 |
Mahamaya Lifesciences Reservation
| Category | Shares Offered | % |
|---|---|---|
| Anchor | 1752000 | 28.36% |
| QIB | 1176000 | 19.03% |
| HNI | 882000 | 14.27% |
| INDIVIDUAL | 2059200 | 33.33% |
| Market Maker | 309600 | 5.01% |
| Total | 6178800 | 100% |
Mahamaya Lifesciences About
Mahamaya Lifesciences IPO Details
| Issue Size | 61,78,800 shares (aggregating up to ₹70.44 Cr) |
| Fresh Issue | 53,29,200 shares (aggregating up to ₹60.75 Cr) |
| Offer for Sale | 5,40,000 shares of ₹10 (aggregating up to ₹6.16 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 1,77,66,200 shares |
| Share Holding Post Issue | 2,34,05,000 shares |
| Reserved for Market Maker | 3,09,600 shares (aggregating up to ₹3.53 Cr) |
| Market Maker | Mansi Share & Stock Broking Pvt.Ltd |
Key Performance Indicator (KPI)
| KPI | Jun-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| ROE | 7.97% | 34.94% | 23.67% |
| ROCE | 7.30% | 23.15% | 16.16% |
| EPS (basic) | 2.31 | 7.6 | 3.26 |
| P/E Pre IPO | 15.65 | ||
| P/E Post IPO | 16.25 |
Company Financials In Crores
| Period | June 2025 | March 2025 | March 2024 | March 2023 |
|---|---|---|---|---|
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| NET Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves | 35.73 | 31.66 | 23.41 | 18.19 |
| Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
Company Overview
The company specializes in pesticide formulations and supplies bulk products to Indian agrochemical firms and MNCs.
It imports researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations.
The company has invested in global product registrations, with active markets in Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey.
Product portfolio includes technical, bulk, branded, and export formulations catering to diverse crop protection needs.
Experienced management and proven capability to introduce vital agricultural products.
Expanding export footprint with high-quality formulations and strong data support.
Objects of the Issue:
Purchase of equipment for existing formulation plant – ₹3.75 crore
Funding capex for new technical manufacturing plant – ₹29.42 crore
Construction of warehouse and machinery purchase – ₹2.53 crore
Funding working capital requirements – ₹18.00 crore
General corporate purposes
Strength
Experienced and Skilled Management Team: The company is managed by professionals with extensive experience in agrochemicals, research, regulatory affairs, and exports, ensuring strategic decision-making and operational excellence.
Diverse Product Portfolio: Offers a wide range of crop protection solutions including insecticides, herbicides, fungicides, and bioproducts in multiple forms—technical, bulk, branded, and export-oriented—enabling flexibility and broad market coverage.
Strong Research and Regulatory Capabilities: Ability to identify and register new molecules with the Central Insecticides Board and secure global registrations enhances the company’s innovation and compliance edge.
Weakness
Customer Concentration: Top 10 customers contributed 71.35%, 76.26%, 83.14%, and 71.12% of total sales for the period ended June 30, 2025, and fiscal years 2025, 2024, and 2023, respectively. Heavy dependence on few customers poses concentration risk.
No Long-Term Contracts: The company does not have long-term agreements with customers or suppliers, making it vulnerable to fluctuations in demand and supply.
Raw Material Price Sensitivity: Raw materials form a major part of total expenses. Any rise in input prices or disruption in supply could adversely affect profitability and operations.
Mahamaya Lifesciences Lead Manager(s)
Mahamaya Lifesciences Address
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
Mahamaya Lifesciences Registrar
Mahamaya Lifesciences Reviewers
| Reviewer | Recommendation | File |
|---|